Ann: CEO presentation to Broker Meets Biotech - Perth, page-61

Reading thru both analyst reports, what struck me is that Morgans do not touch on the likelihood or otherwise of the trial being successful. Indeed, all they really said was "We have set the price target at the same level. The risk to the target is a negative clinical trial read-out. FTT is recommended only for investors with a higher risk profile." In the Lodge Bros's report in contrast, they dwell significantly on this risk. Which investors, might I ask , were better informed after reading these reports?